[go: up one dir, main page]

AR056721A1 - PREPARED STABILIZED ORAL PHARMACEUTICAL CONTAINING CLOPIDOGREL BISULFATO - Google Patents

PREPARED STABILIZED ORAL PHARMACEUTICAL CONTAINING CLOPIDOGREL BISULFATO

Info

Publication number
AR056721A1
AR056721A1 ARP060104644A ARP060104644A AR056721A1 AR 056721 A1 AR056721 A1 AR 056721A1 AR P060104644 A ARP060104644 A AR P060104644A AR P060104644 A ARP060104644 A AR P060104644A AR 056721 A1 AR056721 A1 AR 056721A1
Authority
AR
Argentina
Prior art keywords
bisulfato
oral pharmaceutical
pharmaceutical containing
stabilized oral
containing clopidogrel
Prior art date
Application number
ARP060104644A
Other languages
Spanish (es)
Inventor
Joon Gyo Oh
Dong-Chul Shin
Ji Young Shin
Won-No Youn
Key An Um
Dong-Sun Min
Jae-Sun Kim
Nam Ho Kim
Nam Kyu Lee
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of AR056721A1 publication Critical patent/AR056721A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparado oral estabilizado que incluye clopidogrel bisulfato, y en particular el presente preparado oral comprende además almidon y celulosa junto con la forma cristalina 1 o forma cristalina 2 de clopidogrel bisulfato, que es sensible a la humedad y produce impurezas relacionadas con productos hidratados cuando se formula en preparados orales, mostrando así estabilidad al almacenamiento incluso con la misma forma galénica que los preparados convencionales.Stabilized oral preparation including clopidogrel bisulfate, and in particular the present oral preparation further comprises starch and cellulose together with the crystalline form 1 or crystalline form 2 of clopidogrel bisulfate, which is sensitive to moisture and produces impurities related to hydrated products when formulated in oral preparations, thus showing storage stability even in the same galenic form as conventional preparations.

ARP060104644A 2005-10-24 2006-10-24 PREPARED STABILIZED ORAL PHARMACEUTICAL CONTAINING CLOPIDOGREL BISULFATO AR056721A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020050100460A KR20070044323A (en) 2005-10-24 2005-10-24 Oral solution containing clopidogrel hydrogen sulfate with improved storage stability

Publications (1)

Publication Number Publication Date
AR056721A1 true AR056721A1 (en) 2007-10-17

Family

ID=37967949

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104644A AR056721A1 (en) 2005-10-24 2006-10-24 PREPARED STABILIZED ORAL PHARMACEUTICAL CONTAINING CLOPIDOGREL BISULFATO

Country Status (4)

Country Link
KR (1) KR20070044323A (en)
AR (1) AR056721A1 (en)
TW (1) TW200727898A (en)
WO (1) WO2007049868A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2207533B1 (en) * 2007-10-10 2021-01-06 Avantor Performance Materials, LLC Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
EP2095815B1 (en) 2008-02-26 2011-10-26 Laboratorios Lesvi, S.L. Pharmaceutical formulations containing clopidogrel
KR101324862B1 (en) * 2011-07-12 2013-11-01 (주)에이에스텍 Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof
HUP1400294A2 (en) 2014-06-13 2015-12-28 Skillpharm Kft Novel application of clopidogrel
CN109528669A (en) * 2018-12-25 2019-03-29 哈尔滨珍宝制药有限公司 Bisulfate clopidogrel composition, clopidogrel hydrogen sulfate tablet and preparation method thereof
CN112999180B (en) * 2019-12-20 2022-08-30 青岛黄海制药有限责任公司 Clopidogrel hydrogen sulfate crystal form II tablet and preparation method thereof
CN111166745A (en) * 2020-01-19 2020-05-19 成都施贝康生物医药科技有限公司 Composition and application containing racemic pidogrel or its salt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792836B3 (en) * 1999-04-30 2001-07-27 Sanofi Sa PHARMACEUTICAL COMPOSITION IN UNIT FORM CONTAINING ASPIRIN AND CLOPIDOGREL HYDROGENOSULFATE
CA2363053C (en) * 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
WO2005070464A2 (en) * 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate

Also Published As

Publication number Publication date
TW200727898A (en) 2007-08-01
WO2007049868A1 (en) 2007-05-03
KR20070044323A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
ECSP088082A (en) PIRIDAZINE DERIVATIVES
TW200628161A (en) Novel betulin derivatives, preparation thereof and use thereof
BR0308979A (en) Indolylmaleimide Derivatives
ECSP088549A (en) NEW DERIVATIVES OF FUSIONATED PIRROL
AR072261A1 (en) PIPERAZIN-PIRAZOLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME AS ANTICANCERIGEN AGENTS.
CR9703A (en) DERIVATIVES OF PIRAZOLONA
MY138941A (en) Aryl-pyridine derivatives
TW200626558A (en) Indazolone derivatives
AR064692A1 (en) DERIVATIVES OF OXINDOL REPLACED DRUGS THAT UNDERSTAND AND USE THEMSELVES
MX2009010567A (en) Imidazolidinone derivatives.
BRPI0717035B8 (en) benzotriazole kinase modulators
BRPI0408347A (en) pyrimidine derivatives
MX2010005824A (en) Aminothiazole derivatives.
NO20062098L (en) Faststofftilstandmontelukast
MA33384B1 (en) Heterocyclic sulfonamides, their uses and the pharmaceutical compositions they contain
ATE520406T1 (en) CRYSTALLINE FORM OF IBANDRONATE SODIUM
TW200616940A (en) Novel hexafluoroisopropanol substituted ether derivatives
CY1115623T1 (en) METHOD FOR COMPOSITION OF 7,8-DIMETHOXY-1,3-DIDHYRO-2H-3-BENZAZEPIN-2-ONE AND ITS APPLICATION TO THE SYNTHESIS OF IBABRADYN AS
TW200616976A (en) Pyrimidine derivatives
AR056721A1 (en) PREPARED STABILIZED ORAL PHARMACEUTICAL CONTAINING CLOPIDOGREL BISULFATO
PA8579301A1 (en) DERIVATIVES OF TIAZOL
DE60319707D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A BENZIMIDAZOLE DERIVATIVE MIXED WITH MICROCRYSTALLINE CELLULOSE
MX2009007416A (en) Sulfonamide derivatives as chymase inhibitors.
ATE464043T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING L-ARGININE
BR0114156A (en) Amorphous form of cell cycle inhibitor

Legal Events

Date Code Title Description
FB Suspension of granting procedure